LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes.

    Zettl, Ferdinand / Meister, Toni Luise / Vollmer, Tanja / Fischer, Bastian / Steinmann, Jörg / Krawczyk, Adalbert / V'kovski, Philip / Todt, Daniel / Steinmann, Eike / Pfaender, Stephanie / Zimmer, Gert

    Vaccines

    2020  Volume 8, Issue 3

    Abstract: Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genus ...

    Abstract Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genus
    Keywords covid19
    Language English
    Publishing date 2020-07-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines8030386
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes.

    Zettl, Ferdinand / Meister, Toni Luise / Vollmer, Tanja / Fischer, Bastian / Steinmann, Jörg / Krawczyk, Adalbert / V'kovski, Philip / Todt, Daniel / Steinmann, Eike / Pfaender, Stephanie / Zimmer, Gert

    Zettl, Ferdinand; Meister, Toni Luise; Vollmer, Tanja; Fischer, Bastian; Steinmann, Jörg; Krawczyk, Adalbert; V'kovski, Philip; Todt, Daniel; Steinmann, Eike; Pfaender, Stephanie; Zimmer, Gert (2020). Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines, 8(3) MDPI 10.3390/vaccines8030386

    2020  

    Abstract: ... which can be used at low biosafety level 1 to rapidly quantify SARS-CoV-2-neutralizing antibodies ... available. The detection and quantification of SARS-CoV-2-neutralizing antibodies plays a crucial role ... antibodies, and the evaluation of novel vaccines. To detect SARS-CoV-2-neutralizing antibodies, classically ...

    Abstract Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genus Betacoronavirus, is a pandemic virus, which has caused numerous fatalities, particularly in the elderly and persons with underlying morbidities. At present, there are no approved vaccines nor antiviral therapies available. The detection and quantification of SARS-CoV-2-neutralizing antibodies plays a crucial role in the assessment of the immune status of convalescent COVID-19 patients, evaluation of recombinant therapeutic antibodies, and the evaluation of novel vaccines. To detect SARS-CoV-2-neutralizing antibodies, classically, a virus-neutralization test has to be performed at biosafety level 3, considerably limiting the general use of this test. In the present work, a biosafety level 1 pseudotype virus assay based on a propagation-incompetent vesicular stomatitis virus (VSV) has been used to determine the neutralizing antibody titers in convalescent COVID-19 patients. The neutralization titers in serum of two independently analyzed patient cohorts were available within 18 h and correlated well with those obtained with a classical SARS-CoV-2 neutralization test (Pearson correlation coefficients of r = 0.929 and r = 0.939, respectively). Most convalescent COVID-19 patients had only low titers of neutralizing antibodies (ND50 < 320). The sera of convalescent COVID-19 patients also neutralized pseudotype virus displaying the SARS-CoV-1 spike protein on their surface, which is homologous to the SARS-CoV-2 spike protein. In summary, we report a robust virus-neutralization assay, which can be used at low biosafety level 1 to rapidly quantify SARS-CoV-2-neutralizing antibodies in convalescent COVID-19 patients and vaccinated individuals.
    Keywords 630 Agriculture ; covid19
    Subject code 616
    Language English
    Publishing date 2020-07-15
    Publisher MDPI
    Publishing country ch
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article: Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes

    Zettl, Ferdinand / Meister, Toni Luise / Vollmer, Tanja / Fischer, Bastian / Steinmann, Jörg Krawczyk / Adalbert, V’kovski Philip / Todt, Daniel / Steinmann, Eike / Pfaender, Stephanie / Zimmer, Gert

    Vaccines

    Abstract: ... available The detection and quantification of SARS-CoV-2-neutralizing antibodies plays a crucial role ... at low biosafety level 1 to rapidly quantify SARS-CoV-2-neutralizing antibodies in convalescent COVID-19 ... antibodies, and the evaluation of novel vaccines To detect SARS-CoV-2-neutralizing antibodies, classically ...

    Abstract Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genus Betacoronavirus, is a pandemic virus, which has caused numerous fatalities, particularly in the elderly and persons with underlying morbidities At present, there are no approved vaccines nor antiviral therapies available The detection and quantification of SARS-CoV-2-neutralizing antibodies plays a crucial role in the assessment of the immune status of convalescent COVID-19 patients, evaluation of recombinant therapeutic antibodies, and the evaluation of novel vaccines To detect SARS-CoV-2-neutralizing antibodies, classically, a virus-neutralization test has to be performed at biosafety level 3, considerably limiting the general use of this test In the present work, a biosafety level 1 pseudotype virus assay based on a propagation-incompetent vesicular stomatitis virus (VSV) has been used to determine the neutralizing antibody titers in convalescent COVID-19 patients The neutralization titers in serum of two independently analyzed patient cohorts were available within 18 h and correlated well with those obtained with a classical SARS-CoV-2 neutralization test (Pearson correlation coefficients of r = 0 929 and r = 0 939, respectively) Most convalescent COVID-19 patients had only low titers of neutralizing antibodies (ND50 <320) The sera of convalescent COVID-19 patients also neutralized pseudotype virus displaying the SARS-CoV-1 spike protein on their surface, which is homologous to the SARS-CoV-2 spike protein In summary, we report a robust virus-neutralization assay, which can be used at low biosafety level 1 to rapidly quantify SARS-CoV-2-neutralizing antibodies in convalescent COVID-19 patients and vaccinated individuals
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #653867
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top